BRPI0511695A - agonistas de receptor (beta)2 adrenérgico diamina - Google Patents

agonistas de receptor (beta)2 adrenérgico diamina

Info

Publication number
BRPI0511695A
BRPI0511695A BRPI0511695-3A BRPI0511695A BRPI0511695A BR PI0511695 A BRPI0511695 A BR PI0511695A BR PI0511695 A BRPI0511695 A BR PI0511695A BR PI0511695 A BRPI0511695 A BR PI0511695A
Authority
BR
Brazil
Prior art keywords
adrenergic receptor
diamine
receptor agonists
compounds
beta
Prior art date
Application number
BRPI0511695-3A
Other languages
English (en)
Inventor
Martin Linsell
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BRPI0511695A publication Critical patent/BRPI0511695A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof

Abstract

AGONISTAS DE RECEPTOR <225>~ 2~ ADRENéRGICO DIAMINA A invenção provê novos compostos agonistas de receptor <225>~ 2~ adrenérgico. A invenção também provê composições farmacêuticas compreendendo tais compostos, métodos de uso de tais compostos para tratar doenças associadas à atividade do receptor <225>~ 2~ adrenérgico e processos e intermediários úteis para preparação de tais compostos.
BRPI0511695-3A 2004-06-03 2005-06-02 agonistas de receptor (beta)2 adrenérgico diamina BRPI0511695A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57656004P 2004-06-03 2004-06-03
PCT/US2005/019549 WO2005121065A2 (en) 2004-06-03 2005-06-02 DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS

Publications (1)

Publication Number Publication Date
BRPI0511695A true BRPI0511695A (pt) 2008-01-08

Family

ID=35115813

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511695-3A BRPI0511695A (pt) 2004-06-03 2005-06-02 agonistas de receptor (beta)2 adrenérgico diamina

Country Status (14)

Country Link
US (2) US7402673B2 (pt)
EP (1) EP1751086A2 (pt)
JP (1) JP2008501705A (pt)
CN (1) CN1984876A (pt)
AU (1) AU2005252226A1 (pt)
BR (1) BRPI0511695A (pt)
CA (1) CA2569395A1 (pt)
IL (1) IL179631A0 (pt)
MA (1) MA28902B1 (pt)
MX (1) MXPA06013916A (pt)
NO (1) NO20066016L (pt)
RU (1) RU2006146042A (pt)
WO (1) WO2005121065A2 (pt)
ZA (1) ZA200610835B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
US7402673B2 (en) * 2004-06-03 2008-07-22 Theravance, Inc. Diamine β2 adrenergic receptor agonists
WO2006014704A1 (en) * 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
US7566785B2 (en) * 2004-09-10 2009-07-28 Theravance, Inc. Amidine substituted aryl aniline compounds
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008041914A1 (en) * 2006-10-06 2008-04-10 Astrazeneca Ab 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2303873A4 (en) 2008-06-18 2012-01-04 Astrazeneca Ab BENZOXAZINE DERIVATIVES AS A BETA2 ADRENORE RECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISEASES
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1158082B (de) 1960-12-17 1963-11-28 Gruenenthal Chemie Verfahren zur Herstellung von Alkylendiaminderivaten und deren Salzen
DE1250450B (de) 1962-03-31 1967-09-21 Deutsche Gold- und Silber-Scheideanstalt vormals Roessler, Frankfurt/M Verfahren zur Herstellung von Aminoalkoholen sowie deren Säureadditionssalzen und quartären Ammoniumverbindungen
US3775477A (en) * 1971-03-10 1973-11-27 Sterling Drug Inc N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides
AT310146B (de) 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
BE794414A (fr) * 1972-01-25 1973-07-23 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicament
GB1460593A (en) 1973-06-22 1977-01-06 Ici Ltd Ethanolamine derivatives
JPS5913510B2 (ja) 1975-12-26 1984-03-30 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS5283619A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Alpha-substituted aminomethyl benzyl alcohol derivative
JPS609713B2 (ja) 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US4853381A (en) 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
GB8426200D0 (en) * 1984-10-17 1984-11-21 Glaxo Holdings Ltd Chemical compounds
GB8507942D0 (en) 1985-03-27 1985-05-01 Beecham Group Plc Compounds
EP0233686A3 (en) 1986-01-11 1989-05-03 Beecham Group Plc Bis phenyl ethanol amines and bis phenyoxypropanolamines having a beta-agonist activity
US5223614A (en) 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9713819D0 (en) * 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
MXPA02010179A (es) 2000-04-27 2003-04-25 Boehringer Ingelheim Pharma Nuevos betamimeticos de larga accion, procedimiento para su preparacion y su empleo como medicamentos.
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
MXPA04002405A (es) 2001-09-14 2004-05-31 Glaxo Group Limetd Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1507754A1 (en) * 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
US7402673B2 (en) * 2004-06-03 2008-07-22 Theravance, Inc. Diamine β2 adrenergic receptor agonists

Also Published As

Publication number Publication date
ZA200610835B (en) 2007-11-28
WO2005121065A2 (en) 2005-12-22
RU2006146042A (ru) 2008-07-20
MXPA06013916A (es) 2007-03-07
US7402673B2 (en) 2008-07-22
NO20066016L (no) 2007-02-27
WO2005121065A3 (en) 2006-02-09
US20050272769A1 (en) 2005-12-08
CA2569395A1 (en) 2005-12-22
EP1751086A2 (en) 2007-02-14
IL179631A0 (en) 2007-05-15
JP2008501705A (ja) 2008-01-24
CN1984876A (zh) 2007-06-20
MA28902B1 (fr) 2007-10-01
AU2005252226A1 (en) 2005-12-22
US20080039495A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
BRPI0511695A (pt) agonistas de receptor (beta)2 adrenérgico diamina
BRPI0506823A (pt) derivados de aril anilina como agonistas de receptor beta2 adrenérgico
BRPI0414634A (pt) agonistas de receptor b2, adrenérgico de etilamino amino-substituìdo
BR0213795A (pt) Agonistas do receptor beta-2 adrenérgico de aril anilina
BRPI0507791A (pt) compostos de indazol-carboxamida como agonistas do receptor 5-ht4
DE602005021696D1 (de) Indazolcarbonsäureamidverbindungen
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
ATE495171T1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
BRPI0410946A (pt) derivados de 2-(6-amino-piridin-3-il)-2-hidroxietilamina como agonistas de receptores adrenérgicos beta 2
BRPI0607015A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
TW200510277A (en) Crystalline form of β2-adrenergic receptor agonist
AP1542A (en) Glucocorticoid receptor modulators.
BRPI0611202C1 (pt) compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
WO2007098474A8 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
BRPI0608392A2 (pt) compostos de quinolinona como agonistas do receptor 5-ht4
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
DE602004024383D1 (de) Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
DK1830835T3 (da) Anvendelse af en vanilloid receptorantagonist sammen med et glycosaminoglycan eller proteoglycan til fremstilling af et middel til behandling af smerter
DK1893597T3 (da) AMPA-receptorpotentiatorer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]